Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved symbols : Mrk save search
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.37%
C: 0.1%
health treatment for canada advanced keytruda
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published: 2024-03-28 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
keytruda lung cancer cell risk plus
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.38%
H: 0.24%
C: -0.21%
fda group treatment hypertension
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.0%
H: 0.99%
C: -0.11%
keytruda tumors advanced plus
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published: 2023-11-01 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.83%
H: 0.66%
C: -0.68%
keytruda fda cancer treatment plus gemcitabine
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Published: 2023-10-16 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.18%
H: 1.12%
C: -0.06%
keytruda lung cancer cell treatment risk
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-24 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 1.28%
H: 0.0%
C: 0.0%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.31%
H: 0.96%
C: -1.35%
lynparza japan approved cancer treatment plus
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Published: 2023-08-03 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.59%
H: 0.67%
C: 0.62%
LUMO | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: -5.62%
ervebo fda children
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
Published: 2023-06-06 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -3.12%
prevymis fda disease kidney cytomegalovirus
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2023-06-01 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.23%
H: 0.84%
C: 0.24%
lynparza fda cancer treatment plus
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Published: 2023-03-29 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.09%
H: 0.24%
C: -0.66%
keytruda fda approval tumors
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII, VARIVAX and ProQuad
Published: 2023-03-06 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.73%
H: 3.33%
C: 3.2%
fda
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
Published: 2022-12-21 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.35%
H: 0.99%
C: 0.92%
lynparza treatment approved cancer prostate cancer
Health Canada Approves KEYTRUDA (pembrolizumab) as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC)
Published: 2022-10-12 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.52%
C: -0.91%
treatment canada health renal keytruda cell carcinoma
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Published: 2022-09-27 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.74%
H: 0.93%
C: -1.13%
keytruda cancer
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
Published: 2022-09-22 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 5.36%
H: 0.0%
C: -1.08%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.02%
H: 4.26%
C: 3.5%
lynparza treatment approved china cancer ovarian cancer
Health Canada Approves KEYTRUDA (pembrolizumab) as Adjuvant Treatment for Adults and Children with Stage IIB or IIC Melanoma Following Complete Resection
Published: 2022-09-13 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.95%
H: 0.33%
C: -1.19%
treatment melanoma children canada health keytruda
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Published: 2022-08-04 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -2.17%
H: 0.42%
C: 0.42%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.22%
H: 0.09%
C: -1.13%
lynparza treatment approved cancer her2- her2
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
Published: 2022-06-24 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 3.84%
H: 0.0%
C: 0.0%
keytruda treatment melanoma
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
Published: 2022-06-22 (Crawled : 17:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 3.24%
H: 2.61%
C: 1.27%
fda disease children pneumococcal
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.